Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 9440157 Publication Model: Print Cited Medium: Internet ISSN: 1875-533X (Electronic) Linking ISSN: 09298673 NLM ISO Abbreviation: Curr Med Chem Subsets: MEDLINE
    • Publication Information:
      Publication: Saif Zone, Sharjah, U.A.E. : Bentham Science Publishers
      Original Publication: Schiphol, The Netherlands : Bentham Science Publishers,
    • Subject Terms:
      Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetic Nephropathies*/drug therapy ; Diabetic Nephropathies*/etiology ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/pharmacology; Humans ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/pharmacology
    • Abstract:
      Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the leading cause of renal failure in patients with chronic kidney diseases undergoing hemodialysis. Hence preventing the development and progression of diabetic nephropathy is one of the main goals in the management of patients with type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors of empagliflozin is a potent anti-hyperglycemic agents. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In the current study, we review the available clinical data on the potential renoprotective effects of this drug from a mechanistic and molecular viewpoint.
      (Copyright© Bentham Science Publishers; For any queries, please email at [email protected].)
    • Contributed Indexing:
      Keywords: Type 2 diabetes mellitus; chronic kidney disease; diabetic nephropathy; empagliflozin; renoprotective effects; sodium-glucose cotransporter 2 inhibitor
    • Accession Number:
      HDC1R2M35U (empagliflozin)
      0 (Hypoglycemic Agents)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
    • Publication Date:
      Date Created: 20220901 Date Completed: 20230519 Latest Revision: 20230519
    • Publication Date:
      20240628
    • Accession Number:
      10.2174/0929867329666220831151645
    • Accession Number:
      36045524